J B Chemicals & Pharmaceuticals Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹904Cr
- −4.7% YoY
- −15.1% QoQ
- Net profit
- ₹101Cr
- −30.8% YoY
- −49% QoQ
- Margin
- 22%
- −2 pp YoY
- −6 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
What the Q4 FY26 call signalled
1 of 2 strong
The short version
JB Chemicals aims for gradual recovery to previous growth trajectories post Q4 operational reset. JB Chemicals expects gradual normalization and recovery in growth starting Q1 FY27, post Q4 operational reset.
From J B Chemicals & Pharmaceuticals Ltd's Q4 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- JB Chemicals aims for gradual recovery to previous growth trajectories post Q4 operational reset.
- India business expected to achieve double-digit (low to mid-teens) growth, likely taking a couple of quarters to normalize.
- International business anticipates single-digit growth starting Q2 FY27, factoring in geopolitical challenges.
- CDMO segment has strong growth drivers with multiple signed contracts but faces execution delays; growth momentum expected once execution improves.
- Growth strategies include increasing wallet share with existing top customers (Innova, Kenvue, P&G, Reckitt), expanding geographic footprint, and tapping new large customers globally.
- Merger synergies with Torrent Pharma expected to drive growth in branded business and improve margins.
2 more points from J B Chemicals & Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what J B Chemicals & Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
See what J B Chemicals & Pharmaceuticals Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what J B Chemicals & Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- JB Chemicals and Pharma has several new contracts and projects signed in the CDMO segment with top global customers like Innova, Kenvue, P&G, and Reckitt.
- The company aims to accelerate execution and delivery of these signed contracts to convert them into revenue faster.
- Growth strategy includes increasing wallet share with existing customers by expanding geographic footprint, supplying existing products in additional markets.
2 more points from J B Chemicals & Pharmaceuticals Ltd's call on order book
Create a free account to keep reading this call
J B Chemicals & Pharmaceuticals Ltd — Quarterly revenue & net profit
J B Chemicals & Pharmaceuticals Ltd Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 904 | 949 | -4.7% | 1,065 | -15.1% |
| Operating profit (EBITDA) | 201 | 226 | -11.1% | 296 | -32.1% |
| Operating margin | 22% | 24% | -2 pp | 28% | -6 pp |
| Profit before tax | 135 | 193 | -30.1% | 267 | -49.4% |
| Net profit (PAT) | 101 | 146 | -30.8% | 198 | -49% |
| EPS (₹) | 6.31 | 9.36 | -32.6% | 12.63 | -50% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹904 Cr, net profit ₹101 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What J B Chemicals & Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
J B Chemicals & Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were J B Chemicals & Pharmaceuticals Ltd Q4 FY26 results?
JB Chemicals aims for gradual recovery to previous growth trajectories post Q4 operational reset. JB Chemicals expects gradual normalization and recovery in growth starting Q1 FY27, post Q4 operational reset.
What is J B Chemicals & Pharmaceuticals Ltd share price analysis?
J B Chemicals & Pharmaceuticals Ltd currently shows a below-average growth signal. The stock trades at a P/E of 53.8 with a market cap of ₹38,677 Cr. Investors should review the full earnings analysis for detailed insights.
Keep J B Chemicals & Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
